Free Trial

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Lyell Immunopharma logo
$11.10 0.00 (0.00%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Key Stats

Today's Range
$11.00
$11.15
50-Day Range
$8.69
$13.73
52-Week Range
$7.65
$32.00
Volume
2,902 shs
Average Volume
81,085 shs
Market Capitalization
$213.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Reduce

Company Overview

Lyell Immunopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

LYEL MarketRank™: 

Lyell Immunopharma scored higher than 76% of companies evaluated by MarketBeat, and ranked 253rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lyell Immunopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyell Immunopharma is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyell Immunopharma is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lyell Immunopharma has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lyell Immunopharma's valuation and earnings.
  • Percentage of Shares Shorted

    3.29% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 22.81%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lyell Immunopharma does not currently pay a dividend.

  • Dividend Growth

    Lyell Immunopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.29% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 22.81%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lyell Immunopharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for LYEL on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,817.00 in company stock.

  • Percentage Held by Insiders

    22.30% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lyell Immunopharma's insider trading history.
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LYEL Stock News Headlines

Lyell Immunopharma trading resumes
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
See More Headlines

LYEL Stock Analysis - Frequently Asked Questions

Lyell Immunopharma's stock was trading at $12.80 on January 1st, 2025. Since then, LYEL stock has decreased by 13.3% and is now trading at $11.10.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.80) by $0.91. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0 million. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative trailing twelve-month return on equity of 85.58%.

Shares of Lyell Immunopharma reverse split before market open on Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Top institutional investors of Lyell Immunopharma include ARCH Venture Management LLC (9.48%), MWG Management Ltd. (5.25%), Foresite Capital Management IV LLC (5.18%) and Orland Properties Ltd (3.93%). Insiders that own company stock include Richard Klausner, Richard Klausner, Lynn Seely, Lynn Seely, Sumant Ramachandra, Gary K Lee, Stephen J Hill, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley.
View institutional ownership trends
.

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/12/2025
Today
8/29/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LYEL
CIK
1806952
Fax
N/A
Employees
270
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+35.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($24.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$342.99 million
Net Margins
-552,328.31%
Pretax Margin
-552,328.31%
Return on Equity
-85.58%
Return on Assets
-68.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.65
Quick Ratio
7.65

Sales & Book Value

Annual Sales
$60 thousand
Price / Sales
3,553.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.56 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
19,210,000
Free Float
14,927,000
Market Cap
$213.23 million
Optionable
Optionable
Beta
-0.19
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:LYEL) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners